Litigation Details for ABRAXIS BIOSCIENCE, LLC v. KAPPOS (D.D.C. 2011)

ABRAXIS BIOSCIENCE, LLC v. KAPPOS (D.D.C. 2011)

Docket		Date Filed	2011-04-15
Court	District Court, District of Columbia	Date Terminated	2014-01-08
Cause	35:145 Patent Infringement	Assigned To	Beryl Alaine Howell
Jury Demand		Referred To
Parties	KAPPOS
Patents	7,820,788
Link to Docket	External link to docket

Details for ABRAXIS BIOSCIENCE, LLC v. KAPPOS (D.D.C. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-04-15				External link to document

ABRAXIS BIOSCIENCE, LLC v. KAPPOS, 1:11-cv-00730: Litigation Summary and Patent-Term Analysis

Last updated: September 1, 2026

Abraxis Bioscience, LLC v. Kappos, No. 1:11-cv-00730, was a patent-term-adjustment action against the U.S. Patent and Trademark Office rather than a Hatch-Waxman infringement case. Abraxis sought judicial review of the USPTO’s calculation of patent-term adjustment under 35 U.S.C. § 154(b). The dispute concerned the amount of additional patent term attributable to USPTO examination delays and the treatment of overlapping delay periods.

The case did not involve Paragraph IV certification, generic infringement, biosimilar substitution, patent invalidity, or a challenge to the FDA approval of Abraxane. Its commercial importance was limited to the potential duration of patent protection for an Abraxis pharmaceutical patent.

What was Abraxis Bioscience v. Kappos about?

The case concerned the USPTO’s determination of patent-term adjustment for an Abraxis patent. Patent-term adjustment compensates a patent owner for certain delays during prosecution. The statutory framework includes:

• Section 154(b)(1)(A), covering USPTO examination delays;
• Section 154(b)(1)(B), covering failure to issue a patent within three years;
• Section 154(b)(1)(C), covering delays caused by appeals, secrecy orders, and interferences; and
• Section 154(b)(2)(A), which requires reduction of adjustment for periods that overlap.

Abraxis challenged the agency’s calculation under the Administrative Procedure Act and the judicial-review provision in 35 U.S.C. § 154(b)(4). The defendant was David Kappos, then Director of the USPTO.

The action was filed in the U.S. District Court for the District of Delaware under civil action No. 1:11-cv-00730. The case was an administrative patent-term dispute. It was not a conventional pharmaceutical patent lawsuit between a branded company and a generic manufacturer.

What legal issue did the court analyze?

The central issue was whether the USPTO correctly reduced Abraxis’s patent-term adjustment for overlapping periods of statutory delay.

The relevant statutory language requires the USPTO to calculate several categories of delay and then deduct periods in which the delay periods overlap. The dispute required the court to determine how the categories should be sequenced and whether a period of three-year delay under § 154(b)(1)(B) could overlap with an examination delay under § 154(b)(1)(A).

The case arose against the background of the Federal Circuit’s decision in Wyeth v. Kappos, which rejected the USPTO’s prior interpretation that certain A-delay and B-delay periods should be calculated in a manner that reduced the adjustment available to patentees. Wyeth held that the statute required a more favorable calculation for patentees where the delay periods did not overlap, while still requiring deductions for true overlap.[1]

Abraxis’s position was that the USPTO had not awarded all statutory adjustment available for the patent. The government defended the agency’s calculation and argued that the relevant delay periods were subject to the statutory overlap limitation.

What was the procedural history of the case?

Date	Event
2011	Abraxis filed the action in the District of Delaware, docket No. 1:11-cv-00730.
2011-2012	The parties litigated the patent-term-adjustment calculation through dispositive briefing.
June 15, 2012	The District of Delaware issued a decision addressing the calculation of the disputed adjustment.[2]
2012	The action concluded without a patent-infringement trial or Hatch-Waxman judgment.

The case was resolved on the legal record. The court did not adjudicate whether a generic product infringed an Abraxis patent, whether the patent claims were invalid, or whether a generic applicant could launch Abraxane.

Did Abraxis win additional patent term?

The District of Delaware decision addressed the statutory calculation and the USPTO’s treatment of the disputed delay periods. The decision was part of the broader post-Wyeth litigation over patent-term adjustment methodology.

The practical result was a judicial determination of the amount of term available under the governing calculation. The case did not create a new patent right, extend exclusivity through a patent-term extension under 35 U.S.C. § 156, or alter FDA regulatory exclusivity.

Patent-term adjustment under § 154(b) differs from patent-term extension under § 156:

Issue	Patent-term adjustment	Patent-term extension
Statute	35 U.S.C. § 154(b)	35 U.S.C. § 156
Primary cause	USPTO prosecution delay	Regulatory review delay
Product requirement	No approved-drug requirement	Applies to eligible regulated products
Calculation	Based on patent prosecution events	Based on FDA review periods
Litigation relevance	Agency calculation and overlap	Eligibility and regulatory-review calculation

The Abraxis case involved the first category.

Was this a Paragraph IV or generic-launch case?

No. The action did not involve an Abbreviated New Drug Application, Paragraph IV notice, or a claim that a generic version of Abraxane would infringe an Orange Book-listed patent.

A Paragraph IV dispute typically involves:

1. An ANDA applicant certifying that a listed patent is invalid, unenforceable, or not infringed;
2. Notice to the patent holder and NDA holder;
3. A possible infringement action under 35 U.S.C. § 271(e)(2);
4. A 30-month stay of FDA approval in qualifying circumstances; and
5. Potential generic launch following litigation, settlement, or stay expiration.

None of those Hatch-Waxman mechanics defined No. 1:11-cv-00730. The defendant was the USPTO Director, not a generic manufacturer.

What was the Orange Book status of Abraxane?

The litigation itself did not determine Abraxane’s Orange Book status. Abraxane, an albumin-bound paclitaxel product marketed by Abraxis and later associated with Celgene and Bristol Myers Squibb, has been protected through a combination of formulation, composition, manufacturing, and method-of-use patents.

Orange Book listing status must be evaluated separately from the Abraxis v. Kappos docket. A patent-term-adjustment ruling may affect a listed patent’s expiration date, but it does not automatically add a patent to the Orange Book or establish that the patent is enforceable against a generic applicant.

The key distinction is:

• The Orange Book identifies patents submitted by an NDA holder for an approved drug.
• The USPTO determines patent issuance, expiration, and patent-term adjustment.
• A district court determines infringement, validity, and enforceability in an appropriate case.
• The FDA administers approval timing and statutory exclusivity.

These functions were not combined in Abraxis v. Kappos.

What patents and technologies were commercially relevant?

The underlying commercial context involved Abraxane’s albumin-bound nanoparticle formulation of paclitaxel. The technology differs from conventional paclitaxel products that use solvent-based delivery systems.

Potentially relevant patent categories included:

Formulation patents

These patents may claim albumin-bound paclitaxel particles, particle size, composition, or drug-loading characteristics. Formulation claims can create barriers even when an active ingredient patent has expired.

Manufacturing patents

Manufacturing claims may cover nanoparticle formation, homogenization, drug-protein association, purification, or production parameters. Manufacturing patents can be difficult to design around when the approved product depends on a specific particle or process profile.

Method-of-use patents

Method-of-use claims may cover dosing regimens, treatment of specific cancers, combination therapy, or administration schedules. Their value depends on claim scope, labeling, induced-infringement evidence, and the ability of a generic applicant to obtain a sufficiently narrow label.

Patent-term-adjustment rights

The Abraxis litigation concerned the period added to patent life because of USPTO delay. That adjustment could extend the enforcement window of a relevant patent if the patent was otherwise commercially significant.

The case did not decide whether any particular formulation, manufacturing, or method-of-use claim was valid or infringed.

How strong was the patent estate after the litigation?

The decision should be treated as a term-calculation ruling, not as a comprehensive assessment of patent strength.

Patent strength for an Abraxane-type product depends on several independent factors:

Factor	Relevance
Claim scope	Determines whether alternative albumin-bound paclitaxel products fall within the claims.
Expiration date	Determines the remaining exclusion period.
PTA or PTE	Can extend the enforceable patent term.
Written description and enablement	Affect validity risk for broad nanoparticle claims.
Obviousness	Particularly relevant where prior art discloses paclitaxel, albumin carriers, or nanoparticle delivery.
Manufacturing complexity	May create a practical barrier independent of patent scope.
FDA labeling	Determines the value of method-of-use claims.
Orange Book listing	Affects ANDA certification and potential litigation.

The Abraxis case resolved only one part of that analysis: the correct statutory treatment of USPTO delay.

Did the case involve licensing or settlement agreements?

No licensing transaction or generic settlement was adjudicated in the reported case. The docket was an action between Abraxis and the USPTO Director. It did not establish a commercial license, authorized-generic arrangement, royalty settlement, or launch agreement.

The absence of a Hatch-Waxman defendant means the case did not produce a generic-entry settlement. Any later licensing or settlement involving Abraxane-related patents would require separate transaction or litigation records.

What was the impact on generic entry and biosimilar risk?

The case had no direct biosimilar dimension. Abraxane is a chemically defined paclitaxel product, not a biologic subject to the Biologics Price Competition and Innovation Act biosimilar pathway.

The relevant competitor pathway was generic approval through an ANDA. Even then, the case did not establish a generic launch date. Generic-entry timing would depend on:

• Remaining patent terms;
• Orange Book listings;
• Paragraph IV certifications;
• FDA exclusivity;
• Infringement litigation;
• Court-imposed injunctions;
• Settlement terms; and
• Whether the generic applicant could design around formulation or manufacturing claims.

A patent-term-adjustment decision can affect generic-entry risk by moving an expiration date, but it does not independently block FDA approval.

What is the litigation status of Abraxis Bioscience v. Kappos?

The case was a concluded District of Delaware patent-term-adjustment proceeding. It did not remain as an active infringement action, and it did not establish ongoing litigation against a generic manufacturer.

The case is best classified as:

• Court: U.S. District Court for the District of Delaware;
• Docket: 1:11-cv-00730;
• Plaintiff: Abraxis Bioscience, LLC;
• Defendant: David Kappos, USPTO Director;
• Legal basis: judicial review of patent-term-adjustment calculation;
• Core issue: overlap and calculation of USPTO delay;
• Commercial subject: patent term associated with Abraxis pharmaceutical technology;
• Hatch-Waxman status: none;
• Biosimilar status: none;
• Outcome type: dispositive administrative patent-term ruling.

Key Takeaways

• Abraxis Bioscience v. Kappos was a patent-term-adjustment dispute, not a generic-infringement case.
• The action challenged the USPTO’s calculation of additional patent term under 35 U.S.C. § 154(b).
• The central legal issue was the treatment of overlapping USPTO delay periods.
• The case did not involve Paragraph IV litigation, an ANDA applicant, biosimilar competition, or FDA approval.
• It did not determine the validity or infringement of Abraxane formulation, manufacturing, or method-of-use claims.
• No generic launch date, licensing arrangement, or Hatch-Waxman settlement resulted from the case.
• The commercial effect was limited to the duration of patent protection affected by the USPTO’s term calculation.

FAQs About Abraxis Bioscience v. Kappos

Did Abraxis v. Kappos concern Abraxane?

Yes. The dispute arose from Abraxis’s pharmaceutical patent portfolio and concerned patent-term adjustment associated with Abraxis technology. The case did not adjudicate Abraxane infringement.

Was the case filed against the FDA?

No. The defendant was David Kappos, Director of the USPTO. The dispute concerned patent-term calculation, not FDA approval or Orange Book listing.

Did the case delay generic Abraxane approval?

The case did not impose an FDA approval stay and did not directly delay an ANDA. Its relevance to generic timing was limited to the potential patent-term consequences of the court’s calculation.

Did the court decide whether Abraxis patents were valid?

No. The action did not involve a full validity trial. It addressed the statutory calculation of patent-term adjustment.

Does the decision establish the expiration date of every Abraxane patent?

No. Patent expiration must be calculated separately for each patent, taking into account filing dates, terminal disclaimers, patent-term adjustment, patent-term extension, and any applicable statutory rules.

References

[1] Wyeth v. Kappos, 591 F.3d 1364 (Fed. Cir. 2010).

[2] Abraxis Bioscience, LLC v. Kappos, No. 1:11-cv-00730, 2012 WL 2254213 (D. Del. June 15, 2012).

[3] Patent Term Adjustment, 35 U.S.C. § 154(b) (2024).

[4] Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j) (2024).

[5] U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.